| Headaches in over 12s: diagnosis and management | CG150 | | |
| Endo-SPONGE for treating low rectal anastomotic leak | MTG63 | | |
| Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis | TA756 | | |
| Transanal total mesorectal excision for rectal cancer | IPG713 | | |
| Endobronchial nerve ablation for chronic obstructive pulmonary disease | IPG714 | | |
| Colorectal cancer | NG151 | | |
| Prostate cancer: diagnosis and management | NG131 | | |
| Belimumab for treating active autoantibody-positive systemic lupus erythematosus | TA752 | | |
| Cenobamate for treating focal onset seizures in epilepsy | TA753 | | |
| Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome | TA754 | | |
| ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections | MTG62 | | |
| Pelvic floor dysfunction: prevention and non-surgical management | NG210 | | |
| Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) | TA750 | | |
| Dupilumab for treating severe asthma with type 2 inflammation | TA751 | | |
| Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders | TA748 | | |
| Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) | TA749 | | |
| Synergo for non-muscle-invasive bladder cancer | MTG61 | | |
| Fever in under 5s: assessment and initial management | NG143 | | |
| Givosiran for treating acute hepatic porphyria | HST16 | | |
| Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure | IPG711 | | |
| Coronary sinus narrowing device implantation for refractory angina | IPG712 | | |
| Chronic kidney disease: assessment and management | NG203 | | |
| SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea | DG44 | | |
| Acute heart failure: diagnosis and management | CG187 | | |
| Heart valve disease presenting in adults: investigation and management | NG208 | | |
| Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer | TA746 | | |
| Nintedanib for treating progressive fibrosing interstitial lung diseases | TA747 | | |
| Upadacitinib for treating moderate rheumatoid arthritis | TA744 | | |
| NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal) | TA745 | | |
| Inducing labour | NG207 | | |
| Selpercatinib for treating advanced thyroid cancer with RET alterations | TA742 | | |
| Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management | NG206 | | |
| Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer | TA740 | | |
| Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer | TA741 | | |
| Genicular artery embolisation for pain from knee osteoarthritis | IPG708 | | |
| Laparoscopic renal denervation for loin pain haematuria syndrome | IPG709 | | |
| Percutaneous endovascular forearm arteriovenous fistula creation for haemodialysis access | IPG710 | | |
| Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable | TA739 | | |
| Looked-after children and young people | NG205 | | |
| Tofacitinib for treating juvenile idiopathic arthritis | TA735 | | |
| Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy | TA736 | | |
| Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer | TA737 | | |
| Berotralstat for preventing recurrent attacks of hereditary angioedema | TA738 | | |
| Secukinumab for treating moderate to severe plaque psoriasis in children and young people | TA734 | | |
| Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal) | TA732 | | |
| Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA733 | | |
| DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography | MTG60 | | |
| Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) | TA730 | | |
| Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) | TA731 | | |
| Lateral elbow resurfacing for arthritis | IPG705 | | |
| Transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis | IPG706 | | |
| Transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair | IPG707 | | |
| Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA726 | | |
| Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) | TA727 | | |
| Midostaurin for treating advanced systemic mastocytosis | TA728 | | |
| Sapropterin for treating hyperphenylalaninaemia in phenylketonuria | TA729 | | |
| Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA725 | | |
| Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer | TA724 | | |
| Bimekizumab for treating moderate to severe plaque psoriasis | TA723 | | |
| Magnetic resonance therapy for knee osteoarthritis | IPG702 | | |
| Laparoscopic removal of uterine fibroids with power morcellation | IPG703 | | |
| Hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids | IPG704 | | |
| Babies, children and young people's experience of healthcare | NG204 | | |
| Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement | TA722 | | |
| Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s | NG202 | | |
| Continuous positive airway pressure for the treatment of obstructive sleep apnoea/hypopnoea syndrome | TA139 | | |
| Antenatal care | NG201 | | |
| Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma | TA720 | | |
| Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer | TA721 | | |
| Bronchiolitis in children: diagnosis and management | NG9 | | |
| Inducing and maintaining normothermia using temperature modulation devices to improve outcomes after stroke or subarachnoid haemorrhage | IPG701 | | |
| Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA716 | | |
| Clostridioides difficile infection: antimicrobial prescribing | NG199 | | |
| ENDURALIFE powered CRT-D devices for treating heart failure | MTG33 | | |
| Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal) | TA717 | | |
| Ixekizumab for treating axial spondyloarthritis | TA718 | | |
| Secukinumab for treating non-radiographic axial spondyloarthritis | TA719 | | |
| Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA714 | | |
| Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed | TA715 | | |
| Enzalutamide for treating hormone-sensitive metastatic prostate cancer | TA712 | | |
| Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy | TA713 | | |
| Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA275 | | |
| Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation | TA249 | | |
| Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation | TA256 | | |
| Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation | TA355 | | |
| Atrial fibrillation: diagnosis and management | NG196 | | |
| Plus Sutures for preventing surgical site infection | MTG59 | | |
| Laser lithotripsy for difficult-to-treat bile duct stones | IPG699 | | |
| Percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve | IPG700 | | |
| Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis | TA708 | | |
| Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency | TA709 | | |
| Ravulizumab for treating atypical haemolytic uraemic syndrome | TA710 | | |
| Patient experience in adult NHS services: improving the experience of care for people using adult NHS services | CG138 | | |
| Shared decision making | NG197 | | |
| Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer | TA707 | | |
| Autism spectrum disorder in adults: diagnosis and management | CG142 | | |
| Autism spectrum disorder in under 19s: support and management | CG170 | | |
| Ozanimod for treating relapsing–remitting multiple sclerosis | TA706 | | |
| Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer | TA705 | | |
| Electrohydraulic lithotripsy for difficult-to-treat bile duct stones | IPG698 | | |
| Ex-situ machine perfusion for extracorporeal preservation of lungs (ex-vivo lung perfusion) for transplant | IPG695 | | |
| Transvaginal laser therapy for stress urinary incontinence | IPG696 | | |
| Transvaginal laser therapy for urogenital atrophy | IPG697 | | |
| Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) | TA702 | | |
| Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) | TA703 | | |
| Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies | TA704 | | |
| Heavy menstrual bleeding: assessment and management | NG88 | | |
| HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography | MTG32 | | |
| Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcers | MTG20 | | |
| Ravulizumab for treating paroxysmal nocturnal haemoglobinuria | TA698 | | |
| Ofatumumab for treating relapsing multiple sclerosis | TA699 | | |
| Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) | TA701 | | |
| Tafamidis for treating transthyretin amyloidosis with cardiomyopathy | TA696 | | |
| Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban | TA697 | | |
| Permanent His-bundle pacemaker implantation for treating heart failure | IPG694 | | |
| UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia | MTG58 | | |
| Repetitive short-pulse transscleral cyclophotocoagulation for glaucoma | IPG692 | | |
| Deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults | IPG693 | | |
| Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy | TA692 | | |
| Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia | TA694 | | |
| Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma | TA695 | | |
| Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver | IPG691 | | |
| Avelumab for treating metastatic Merkel cell carcinoma | TA517 | | |
| Acalabrutinib for treating chronic lymphocytic leukaemia | TA689 | | |
| Avelumab for untreated metastatic Merkel cell carcinoma | TA691 | | |
| Postnatal care | NG194 | | |
| Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain | NG193 | | |
| Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroids | IPG689 | | |
| Extracorporeal whole liver perfusion for acute liver failure | IPG690 | | |
| Danis stent for acute oesophageal variceal bleeding | MTG57 | | |
| Anakinra for treating Still's disease | TA685 | | |
| Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) | TA686 | | |
| Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy | TA687 | | |
| Selective internal radiation therapies for treating hepatocellular carcinoma | TA688 | | |
| Cannabis-based medicinal products | NG144 | | |
| Asthma: diagnosis, monitoring and chronic asthma management | NG80 | | |
| QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiography | DG43 | | |
| Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease | TA684 | | |
| Erenumab for preventing migraine | TA682 | | |
| Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer | TA683 | | |
| Alpha-Stim AID for anxiety disorders | MTG56 | | |
| Free-functioning gracilis transfer to restore upper limb function in brachial plexus injury | IPG687 | | |
| Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosis | IPG688 | | |
| Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma | TA680 | | |
| Baricitinib for treating moderate to severe atopic dermatitis | TA681 | | |
| Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing | NG190 | | |
| Safeguarding adults in care homes | NG189 | | |
| Metreleptin for treating lipodystrophy | HST14 | | |
| Filgotinib for treating moderate to severe rheumatoid arthritis | TA676 | | |
| Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma | TA677 | | |
| Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) | TA678 | | |
| Dapagliflozin for treating chronic heart failure with reduced ejection fraction | TA679 | | |
| Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy | TA673 | | |
| Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) | TA674 | | |
| Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal) | TA675 | | |
| Trabectedin for the treatment of advanced soft tissue sarcoma | TA185 | | |
| Leukomed Sorbact for preventing surgical site infection | MTG55 | | |
| Mepolizumab for treating severe eosinophilic asthma | TA671 | | |
| Brolucizumab for treating wet age-related macular degeneration | TA672 | | |
| Brain tumours (primary) and brain metastases in over 16s | NG99 | | |
| Self-expanding implant insertion into the intersphincteric space for faecal incontinence | IPG685 | | |
| Minimally invasive radical hysterectomy for early stage cervical cancer | IPG686 | | |
| The VAC Veraflo Therapy system for acute infected or chronic wounds that are failing to heal | MTG54 | | |
| Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor | TA670 | | |
| The PLASMA system for transurethral resection and haemostasis of the prostate | MTG53 | | |
| Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer | TA668 | | |